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Abstract 
The aggregation of proteins into amyloid fibrils and their deposition into plaques and intracellular 
inclusions is the hallmark of amyloid disease. The accumulation and deposition of amyloid fibrils, 
collectively known as amyloidosis, is associated with many pathological conditions such as 
ůǌŚĞŝŵĞƌ ?Ɛdisease ĂŶĚWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ, type II diabetes, and dialysis related amyloidosis. 
However, elucidation of the atomic structure of amyloid fibrils formed from their intact protein 
precursors and how fibril formation relates to disease has remained elusive. Recent advances in 
structural biology techniques, including cryo-electron microscopy (cryo-EM) and solid state NMR 
(ssNMR), have finally broken this impasse. The first near-atomic resolution structures of amyloid 
fibrils formed in vitro, seeded from plaque material, and analysed directly ex vivo are now available. 
The results reveal cross-E structures which are far more intricate than anticipated. Here, we describe 
these structures, highlighting their similarities and differences. We also discuss how amyloid 
structure may affect the ability of fibrils to spread to different sites in a prion-like manner, along 
with their roles in disease. These molecular insights will aid in understanding the development and 
spread of amyloid diseases and are inspiring new strategies for therapeutic intervention. 
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[H1] Introduction  
Despite the first observation of amyloid deposits nearly four centuries ago (Figure 1)1, it has been a 
long wait to see the structures of amyloid fibrils associated with devastating conditions such as 
ůǌŚĞŝŵĞƌ ?ƐĂŶĚWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞin atomic detail. However, in the last two years fibril structures 
have been determined in near atomic detail, thanks to developments in methods to create fibrils in 
vitro, or to purify them from ex vivo material, as well as breakthroughs in cryo-electron microscopy 
(cryo-EM) and solid state nuclear magnetic resonance spectroscopy (ssNMR). Together these 
methods have revealed the structures of amyloid fibrils implicated in some of the gravest of human 
diseases: AE40/42 and tau ĂƐƐŽĐŝĂƚĞĚǁŝƚŚůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ (AD)2,3 and D-synuclein associated with 
WĂƌŬŝŶƐŽŶ ?Ɛ disease4. Although, as expected, the fibrils adopt the canonical cross-E structure of 
amyloid (see below), these fibrils are more complex and elaborate than suspected previously, 
suggesting that a wide variety of amyloid structures may exist, reminiscent perhaps of the different 
organisation of D-helices and E-strands in globular proteins (1375 distinct folds in globular proteins 
have been identified to date5). Such diversity may explain why amyloid diseases are so difficult to 
understand and to treat, with different clinical presentations, even when aggregation of the same 
protein is the culprit. Understanding the molecular architecture of amyloid fibrils may be an 
important step towards development of therapeutic interventions based on targeting the fibrils 
themselves, or the processes that generate them.  
 
Approximately 50 different proteins or peptides are currently known to assemble into amyloid fibrils 
associated with human disease6 (Table 1). These precursors, each with a different primary sequence, 
self-assemble into amyloid fibrils that accumulate into extracellular plaques and intracellular 
inclusions associated with disease, which are especially prevalent during ageing7,8. Emerging 
evidence has shown that intracellular inclusions of amyloid can interfere with cellular physiology, for 
example by disrupting transport of proteins and RNA9 and by sequestering chaperones and 
proteasomes10. Plaques from different phenotypic forms of the same disease can also accumulate 
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different proteins11 and non-protein components12,13 to varying extents, potentially providing clues 
to the different phenotypes observed within an amyloid disease.  
 
Amyloid fibrils share a common underlying architecture, in which the E-strands within each 
protofilament align perpendicular to the long axis of the fibril, ƚĞƌŵĞĚĂ ‘cross-E' amyloid fold 
(Figure 2) marked by a characteristic ~4.7/4.8 Å repeat running down the fibril axis. This structure 
has the strength of steel14,15 and, based on its simplicity and ease of formation, has also been 
proposed as a potential primordial structure of life16. Amyloid can either be functional (in bacteria, 
fungi and higher eukaryotes)17-26 or disease-associated (Table 1) with both types of fibril sharing the 
canonical cross-E architecture unique to the amyloid fold. 
 
Here, we first review the history of our understanding of the amyloid fold, reporting a timeline of 
discovery from the 17th century to the present day (Figure 1). We then describe our current 
understanding of amyloid fibril structure, inspired by recent reports of fibrils formed from proteins 
associated with human disease27,28. We also discuss how amyloid forms, and the relationship 
between protein sequence, fibril morphology and plaque formation, including how these impact on 
disease presentation and progression. Finally, despite recent high-profile setbacks in developing 
drugs to treat amyloid diseases29-32, we speculate on how this new, atom-precise vision of amyloid 
may transform our efforts to treat disease. 
 
[H1] Fibril Formation and Disease 
Our understanding of how amyloid fibrils relate to their associated diseases has expanded rapidly in 
recent years, but from the initial identification of amyloid to the atomic models we have today has 
been a journey over nearly 400 years.  
 
[H2] A Timeline of Amyloid Discovery  
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First described in 1639 as lardaceous liver and  ‘ǁŚŝƚĞƐƚŽŶĞ ?-containing spleen1 ?ƚŚĞƚĞƌŵ ‘ĂŵǇůŽŝĚ ?
(derived ĨƌŽŵƚŚĞ>ĂƚŝŶ ‘ŵǇůƵŵ ?ĂŶĚ'ƌĞĞŬ ‘ŵǇůŽŶ ?ŵĞĂŶŝŶŐƐƚĂƌĐŚ-like), was coined ~200 years 
later by Virchow based on his discovery that these deposits stained positively with iodine1,33. Just 
five years after its misidentification as a polysaccharide, Friedrich and Kekulé showed that amyloid is 
predominantly proteinaceous1, with carbohydrates, specifically glycosaminoglycans, being 
ubiquitously associated with these deposits34. Developments in light microscopy, combined with the 
finding that amyloid deposits show the unique tinctorial property of red-green birefringence in the 
presence of Congo red35, revealed that amyloid is formed of highly organised protein subunits. The 
identification of amyloid A36 (in 1971), antibody light chains37 (in 1971), and transthyretin (TTR)38 (in 
1978) as the major protein component of fibrils in plaques showed that an individual protein 
precursor can be responsible for an amyloid disease. In the meantime, ŝůůƐƚďƵƌǇ ?ƐƉŝŽŶĞĞƌŝŶŐy-ray 
fibre diffraction studies had shown that amyloid-like fibrils could be created from normally globular, 
soluble proteins by denaturing them in vitro39, opening the door to synthetic materials which 
Astbury hoped would replace wool40. In 1968 Sandy Geddes, Bill Aiken and colleagues, working in 
ƐƚďƵƌǇ ?ƐĞƉĂƌƚŵĞŶƚŽĨŝŽƉŚǇƐŝĐƐ at the University of Leeds, used X-ray fibre diffraction to reveal 
that the egg stalk of the lacewing fly also has a distinct ~4.7Å repeating feature down the fibril axis, 
ǁŚŝĐŚƚŚĞǇŶĂŵĞĚ ‘ĐƌŽƐƐ-E ?41. This ground-breaking work established a structural fingerprint for 
amyloid and showed that amyloid is not simply associated with disease, but can be beneficial to an 
organism42-47 (Table 1). 
 
In the 40 years since Geddes et al. ĐŽŝŶĞĚƚŚĞƚĞƌŵ ‘ĐƌŽƐƐ-E ?41, information about the structure of 
amyloid fibrils has been drip-fed to the scientific community, with tantalising insights coming from 
studies of fibrils formed from short peptides using X-ray fibril diffraction48, X-ray crystallography49-51, 
micro-electron diffraction (micro-ED)52 of microcrystals53-56, ssNMR57-66, and cryo-EM27,28,67-72. The 
ability to assemble fibrils in vitro from synthetic peptides73-75 and naturally-occurring amyloidogenic 
proteins and peptides76-78, or from proteins not associated with functional amyloid or disease68,79, 
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has fuelled developments from each structural technique. However, the most recent and exciting 
breakthroughs have been enabled by the step change in the resolving power of cryo-EM that is 
currently revolutionising structural biology80 (Box 1). Combining these techniques has finally cracked 
the amyloid fold, revealing structures that are as beautiful and intricate as those of their globular 
counterparts27,28. These structures give us the first glimpse of how individual protein subunits form 
cross-E structure, and by combining these data with insights from super-resolution microscopy81,82, 
cryo-electron tomography (cryo-ET)13,83,84 and ssNMR 85, we are entering a new era of integrative 
structural biology which allows us to  ‘ƐĞĞ ?ƚŚĞƐƚƌƵĐƚƵƌĞof amyloid fibrils on multiple scales, from 
individual subunits and how they form fibrils, to the cellular consequences of fibril deposition into 
plaques and tangles.  
 
[H2] Diseases Associated with Amyloid Fibril Deposition  
Alois Alzheimer reported the first documented case of ůǌŚĞŝŵĞƌ ?Ɛ disease (AD) in his patient, 
Auguste Deter, in 1901 (Figure 1)86. This work, which included the post-mortem visualisation of 
Congo-red positive plaques in the brain, added ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞƚŽƚŚĞŐƌŽǁŝŶŐůŝƐƚŽĨ
amyloidoses. Today, over 50 disease-causing amyloidogenic proteins have been identified, that give 
rise to an even greater number of diseases, depending on the sequence of the precursor and the site 
of amyloid deposition87-89 (Table 1). This includes neurodegenerative disorders such as AD (involving 
aggregation of AE90 and/or tau2), Creutzfeldt-Jakob disease (prion protein (PrP))91, Huntington ?Ɛ
disease (huntingtin92), PD (D-synuclein93) and amyotrophic lateral sclerosis (ALS) (superoxide 
dismutase, TDP43 and others94). Amyloid disorders affect other tissues: type II diabetes involves the 
aggregation of amylin (otherwise known as islet amyloid polypeptide (IAPP)95) in the islets of 
Langerhans, while in AL amyloidosis antibody light chains deposit in the kidney and heart96 and in 
dialysis-related amyloidosis E2-microglobulin (E2m) forms amyloid plaques in the osteoarticular 
tissues97. There is also crosstalk between amyloid diseases. For example, patients with type II 
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diabetes have a higher risk of AD98, and the non-amyloid component (NAC) of D-synuclein has been 
found in the plaques of patients with AD99.  
What initiates the onset of amyloid disease remains unclear. Many of the diseases are associated 
with ageing and involve the aggregation of wild-type proteins, including most cases of PD and AD8. 
Owing to the ageing of the human population, the estimated economic burden in Europe from AD 
and PD alone is estimated to rise to  ? ? ? ? billion by 2050100, comparable to the GDP of Austria in 
2016. Mutations in amyloidogenic precursors can cause diseases to present earlier, such as the D-
synuclein variants A30P or A53T in PD101, the AEvariants E22A? or E22K in AD102, or D76N in E2m-
associated amyloidosis103 (Table 1). Other disorders are caused by the duplication of an 
amyloidogenic sequence, such as the trinucleotide repeat diseases that result in polyglutamine-
associated ataxias ƐƵĐŚĂƐ,ƵŶƚŝŶŐƚŽŶ ?Ɛ92,104, poly-alanine expansions in the protein PABPN1105 
associated with oculopharyngeal muscular dystrophy106, or dipeptide expansions such as poly-GlyAla 
in C9orf72, the most common genetic form of ALS and frontotemporal dementia107,108. The age of 
onset for people with these diseases is variable, as a critical threshold number of repeats determines 
their pathogenicity, and the rate of disease onset correlates with the number of repeats104,109.  
Modification of a precursor ?Ɛ primary sequence, for example truncations by the action of proteases 
or hyper-phosphorylation, can enhance or suppress amyloidogenicity. Trimming the precursor 
protein can reduce amyloidogenicity, evidenced by the lower risk of AD in patients with an increased 
ratio of AE40 to AE42110. In contrast, proteolysis of apoA1 increases the risk of amyloidosis in systemic 
amyloidosis111 (Table 1), and truncation of the N-terminal six amino acids of E2m is observed in 
dialysis related amyloidosis112,113 (Table 1). Simply increasing the concentration of the monomeric 
precursor by gene duplication can also cause disease, with gene duplication, triplication, or even 
quadruplication associated with the early onset of PD93,114, and patients with trisomy of 
chromosome 21, which encodes Amyloid Precursor Protein (APP) (from which AE40/42 are derived), 
have a higher risk of AD115. The inability of haemodialysis to remove wild-type E2m from the serum 
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of patients with renal failure causes a ~50-fold increase in E2m concentration in the serum116. This 
can result in dialysis-related amyloidosis in patients undergoing long term (> 10 years) renal 
replacement therapy116. Finally, amyloidogenicity can be modulated by small molecules such as 
metabolites or metal ions, by membranes and glycosaminoglycans, and by the status of the cell itself 
(chaperone levels, rate of protein synthesis etc.) which impact on the rate of protein aggregation 
and the ability of the cell to respond to the formation of potentially toxic species9,117.  
 
The ability of amyloid to seed its own assembly, causing disease to spread between cells and, in 
some cases, between organisms is a hallmark of prion diseases118,119. In mammals, PrP causes a 
family of diseases known as the transmissible spongiform encephalopathies91. The soluble, D-helical 
protein, PrPC can conformationally rearrange to an infectious isoform, PrPSc, which has E-sheet 
structure (a process that is not yet understood in atomic detail). As an infectious agent, PrPSc is 
believed to be devoid of nucleic acid120, although this is contested by some studies121. There are 
many prion diseases in humans, such as Creutzfeldt-Jakob disease (CJD), familial fatal insomnia (FFI), 
Gerstmann-Sträussler-Scheinker disease (GSS) and Kuru, which result in different diseases 
characterised by different lengths of onset122. Bovine spongiform encephalopathies (BSE) in cattle, 
chronic wasting disease in deer and elk, and scrapie in sheep and goats123, have also been identified 
as transmissible spongiform encephalopathies. BSE can cross the species barrier to humans, leading 
to variant CJD (vCJD)119,120. Whilst prion diseases are predominantly neurological, in vCJD PrPSc can 
be found in different tissue types124. Prion-like spreading of disease within the brain is not unique to 
PrP, it is also observed in both PD125 and AD126, suggesting that common mechanisms may exist by 
which protein aggregation spreads and causes cell death. In yeast, prion-like spreading of protein 
aggregates, such as those formed from the proteins Ure2p and Sup35, can be beneficial, endowing 
metabolic advantages to daughter cells under certain selective pressures127. Indeed the large 
number of prion-like domains identified in yeast128 suggest that such selective advantages may be 
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commonly adopted giving enhanced fitness. 
 
[H1] Mechanisms of Fibril and Plaque Formation  
Amyloid is formed by the aggregation of monomeric protein precursors into fibrils by a common 
nucleation growth mechanism129,130 (Figure 2). Monomeric precursors may be unfolded (intrinsically 
disordered), or partially folded (formed by transient unfolding of a native protein or transient folding 
of an unfolded protein) (Table 1). In rare cases, aggregation may be initiated by the native protein 
itself131. The first step in fibril assembly involves the formation of oligomers which are dynamic, 
transient, heterogeneous, and of unknown and possibly varied structure130,132,133. Oligomers can then 
further associate to produce higher-order species, which can be either essential precursors of 
amyloid fibrils (on-pathway), or dead-end assemblies that do not produce fibrils (off-pathway)130. 
Whilst off-pathway oligomers do not go on to form fibrils they may still be cytotoxic and relevant to 
disease. At some stage during oligomerisation a critical nucleus is formed, which is defined 
kinetically as the most unstable (highest energy) species formed before rapid polymerisation into 
amyloid fibrils. The probability of nucleus formation determines (in part) the length of the lag time 
of amyloid assembly, and possibly the age of disease onset (Figure 2).  
 
At some point during self-assembly, each precursor undergoes a structural transformation to form 
E-strand rich secondary structure, irrespective of its initial fold (Table 1). Once fibrils with a cross-E 
structure form, they can fragment, producing new fibril ends that can recruit monomers, reducing 
the length of the lag time and resulting in exponential fibril growth (the elongation phase shown in 
in Figure 2)134 Other processes, such as secondary nucleation, where oligomer formation is catalysed 
on the surface of a pre-existing fibril, also enhances the rate of fibril formation130,135. Understanding 
each process, and how they combine to determine the rate of fibril assembly (and hence fibril load), 
is vital for elucidation of the mechanism of fibril formation in both in vitro and in vivo environments.  
 
10 
 
Various models, inspired by work on Sickle cell disease by Eaton, Oosawa and colleagues136,137, 
including both numerical134,138 and analytical approaches139, allow the individual steps of amyloid 
formation to be kinetically defined, by employing simple-to-use algorithms now available on line134. 
The kinetics of assembly are commonly measured in vitro using the dye thioflavin T (ThT), which 
binds to amyloid fibrils, generating an enhanced fluorescence signal139,140. Using this approach, the 
effect of synthetic membranes141, solution conditions142, molecular chaperones143, small 
molecules144, and the primary sequence135 on the rate of aggregation can be elucidated. Most 
importantly, the ability to determine the role of different additives on assembly offers the 
opportunity to control aggregation by the synergistic application of reagents that target different 
steps in amyloid formation.  
 
[H1] Cytotoxicity and Implications for Disease  
Identifying the toxic species formed during amyloid formation, and how they cause cellular 
dysfunction and death, remains both a challenge and a priority (Figure 3). Questions abound, 
including how aggregation is initiated, how aggregates are recognised by chaperones and other 
cellular components, and how and why aggregates saturate the cellular chaperone and degradation 
networks145-147? Models of amyloid-associated cytotoxicity include inhibition of proteasomal 
degradation10,145, impairment of autophagy148, perturbation of mitochondrial function149, production 
of reactive oxygen species (ROS)150, sequestration of other proteins117, and disruption of membranes 
(including mitochondria, the endoplasmic reticulum (ER), lysosomes, and plasma 
membranes)84,117,151,152 (Figure 3).  
 
Critically, the severity of cognitive decline in AD patients does not correlate with plaque formation153 
suggesting that pre-amyloid aggregates may be the cause of disease132,133,154-158. Consistent with this 
view, numerous experiments in vitro have demonstrated the cytotoxicity of oligomeric species, 
including their ability to disrupt membranes159-161. Oligomers formed from proteins not normally 
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associated with disease can also disrupt membranes and can be cytotoxic, adding weight to the view 
that oligomers are the causative agents of amyloid-associated cellular dysfuntion156,160,161. Oligomers 
formed from disease-related precursors have also been shown to impair memory and long-term 
potentiation, again supporting their role in disease162,163. However, not all oligomers are toxic164,165. 
What is known is that toxic oligomers expose hydrophobic surfaces not found in innocuous 
precursors or non-toxic counterparts166, consistent with their ability to perturb membranes and 
expose the cytoplasm to the extracellular space, causing calcium flux and ultimately cell death158,167. 
The molecular basis for an oligomer ?s cytotoxicity will remain unclear until a high-resolution 
structure of a toxic oligomer is solved. However, since oligomers are unstable, dynamic and 
heterogeneous in mass and structure168,169, determining their structure-function relationships is 
challenging. 
 
Recent experiments have re-energised the debate about how, or if, amyloid fibrils contribute to 
disease170. Using cryo-ET, amyloid fibrils and, in particular their ends, have been shown to perturb 
artificial lipid membranes (including breaks, blebbing, and formation of pinched sharp points with 
high membrane curvature)171 and to cause pinching of cellular membranes84, suggesting a role for 
fibrils in disease. Cryo-ET also showed that intracellular inclusions formed from exon 1 of huntingtin, 
which contains 97 glutamines, localise to the rough ER, perturbing ER function and dynamics84. 
Interestingly, extracellular assemblies of AE42 fibrils in cell culture take distinct forms, including 
meshworks, semi-ƉĂƌĂůůĞůďƵŶĚůĞƐ ?ĂŶĚ ‘ƐƚĂƌƐ ?ƌĂĚŝĂƚŝŶŐŽƵƚĨƌŽŵĂĐĞŶƚƌĂůƉŽŝŶƚ13,83. These fibrils also 
interact with membranes, sequestering lipids, and forming tubular inclusions at the cell surface83. 
Intracellular inclusions from the ALS-related protein c9Orf72 sequester proteasomes and impair 
proteasome activity10, demonstrating that fibrillar assemblies from different proteins have different 
cellular effects. In support of this view, NMR metabolomics showed that monomeric, oligomeric and 
fibrillar ɲ-synuclein and Aɴ40/42 have different metabolic effects in neuroblastoma cells, the results 
suggesting that cells attempt to counter the toxicity imposed by pre-fibrillar species, whereas fibrils 
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led to cellular shutdown172. Recent experiments have also shown that different fibril morphologies, 
even when formed from the same protein, can cause different cellular effects presumably by binding 
to different molecules and/or by depositing in different locations60,173-179. For example, two-fold 
symmetric (2A) and three fold symmetric (3Q) fibrils of AE40 bind the glycosaminoglycan, heparin, 
with different affinities12,180, while other fibrils bind to specific RNA molecules or other proteins117. 
Finally, the role of fibril structure in disease is being studied. For example, fibrils from brain extracts 
of AD patients show distinct size, concentration and conformational characteristics, which correlate 
with disease duration and severity181.  
 
While it is fascinating to dissect the effects of different oligomers and fibrils in cellular dysfunction, it 
is likely that a combination of species will correlate with disease. Amyloid formation is a dynamic 
process, with monomers and oligomers in rapid exchange with each other142. Oligomers can also be 
generated directly, by loss of monomers and/or oligomers from fibril ends182,183 (Figure 2). This 
phenomenon may be enhanced by the cellular environment, such as the low pH of endosomes and 
lysosomes182. The protein concentration in cells is also finely tuned, with tight coupling of the rates 
of protein synthesis and degradation to keep proteins within their solubility limit184,185. Given this 
balance, it is perhaps not surprising that over-production of a protein can trigger wholesale 
aggregation of susceptible proteins that are at the cusp of their solubility in the cell186-188. Precursor 
mutation, changes in post-translational modifications, stress or ageing can also result in a 
breakdown of these usually highly protective networks, leading to aggregation.  
 
What emerges from a consideration of this complex network of interactions is the need to elucidate 
the structures of protein aggregates at atomic resolution. This would help us to understand how 
these aggregates perturb cells in molecular detail and to identify methods and molecules that can 
help control protein aggregation, with beneficial effects on cellular dysfunction and disease. 
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[H1] Diversity of Amyloid Structures at High Resolution  
Amyloid fibrils are held together by large variety of inter-monomer and inter-fibril interactions. The 
particular modes of interaction vary in different fibril structures formed from the same protein, as 
well as fibrils formed from different proteins. These interactions affect the physical properties of the 
fibril assemblies, which may contribute with the phenotypic effects observed for different fibril 
polymorphs.  
 
[H2] Amyloid Fibril Structure at the Subunit Level 
The defining structural feature of amyloid fibrils is the  ‘ĐƌŽƐƐ-E ?fold that all fibrils share. This 
 ‘amyloid fold ? involves a ladder of stacked E-strands oriented perpendicular to the fibril axis, with 
each  ‘rung ? of the cross-E ladder separated by a 4.7-4.8 Å spacing that arises from the regular 
hydrogen bond distance between paired carbonyl and amide groups in adjacent E-strands (Figure 4). 
This spacing was first demonstrated in 1968 W1969 using X-ray fibre diffraction (Figure 1)41,189, and is 
found in all amyloid fibrils irrespective of the sequence of the protein precursor. The presence of the 
cross-E conformation has now been verified as ubiquitous in amyloid fibrils, whether functional or 
disease-related, using X-ray fibre diffraction190, X-ray crystallography63, cryo-EM191 and Fourier 
transform infrared spectroscopy (FTIR)192. In FTIR the strong hydrogen bonds between adjacent E-
strands in the cross-Efold absorb at a characteristic frequency of ~1618cm-1, whereas the more 
twisted, less stable, E-sheets in globular proteins absorb at longer wavelengths193,194.  
 
It is important to note that there are several fibrillar structures that are not considered to be 
amyloid despite sharing some traits. For example, small aromatic molecules (such as 
diphenylalanine195) assemble into fibril-like structures stacked with a 3.4 Å spacing and stabilised by 
pi-stacking interactions196. Because these structures are not composed of protein they are generally 
not considered amyloid, despite their structural similarity and the fact that they are also deleterious 
to cells196. Other proteinaceous assemblies have features reminiscent of amyloid but violate some of 
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the defining characteristics of the amyloid fold. For example, short helix-turn-helix peptides 
assemble into twisted fibrils, stabilised by stacked D-helices197. Fibrils in which D-helices, rather than 
E-strands, orient perpendicular to the fibril axis (so-called cross-D) are also found in vivo198 where 
they are important for biofilm formation in Gram-positive organisms198. A toxic oligomer of 
superoxide dismutase 1 (SOD-1), associated with ALS (Table 1), also shares many structural and 
pathological characteristics with amyloid. This assembly is also not considered as a canonical 
amyloid, however, as its E-sheets ĂƌĞĂƌƌĂŶŐĞĚŝŶĂĐŽƌŬƐĐƌĞǁƐƚĂĐŬĂƚĂŶ ? ? ?ȗĂŶŐůĞƚŽƚŚĞĨŝďƌŝů axis, 
akin to an extended E-barrel199. A similar structure has been observed in an oligomer called 
cylindrin, assembled from a E-hairpin peptide derived from DE-crystallin200. Interestingly, this 
cylindrin structure is toxic to HeLa and HEK293 cells200. 
 
Although the 4.7/4.8 Å stacked E-strand motif is the signature of amyloid, some amyloid fibrils also 
share features at a larger length scale. Some of the earliest EM observations of fibrils isolated from 
ƉĂƚŝĞŶƚƐƉůĞĞŶƐĚĞƐĐƌŝďĞĚ ‘ďĞĂĚƐ ?ǁŝƚŚĂŶĂƉƉƌŽǆŝŵĂƚĞůǇ ? ? ?ƉĞƌŝŽĚŝĐŝƚǇĚŽǁŶƚŚĞĨŝďƌŝůĂǆŝƐ201. 
Later cryo-EM studies of fibrils formed in vitro from PrP and E2m reported repeats of ~60 Å202 or 52.5 
Å203, respectively, in addition to the canonical ~4.7Å cross-E repeat, suggestive of higher order 
repeating structures. These longer repeats have not been observed in the high resolution structures 
of tau or AE42 fibrils reported recently27,28, leaving the structural basis of these larger repeats open to 
debate.  
 
Other common features are found in the subunit structures of amyloid fibrils regardless of the 
sequence and structure of their precursor (Table 1). In all cases, the subunit structure adopted 
within the fibril is dramatically different to that of the native protein (Table 1). Thus, a major 
structural conversion must occur as amyloid forms: from unfolded to E-strand, D-helical to E-strand, 
or reorganisation of pre-existing E-sheet structures (Table 1). Despite the commonality of their 
cross-E fold fibril structures are not identical, with recent studies revealing a remarkable diversity of 
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architectures that all conform to the amyloid fold (Figure 5). A 10-residue peptide from TTR67 forms 
antiparallel E-ƐƚƌĂŶĚƉĂŝƌƐ ?ǁŝƚŚĞĂĐŚƉĞƉƚŝĚĞĨŽƌŵŝŶŐŽŶĞ ‘ƌƵŶŐ ?ŽĨƚŚĞĐƌŽƐƐ-E ladder, while AE40 
forms distinct fibril structures that have an in-register parallel organisation of their E-strands, but 
differ in the precise location and/or organisation of their E-loop-E motif (Figure 5c)204,205. In larger, 
proteins, multiple sets of antiparallel E-shĞĞƚƐ ?ƚĞƌŵĞĚ ‘ƐƵƉĞƌƉůĞĂƚĞĚE-sheets ?, were predicted for a 
Ure2p prion filament206 and IAPP fibrils207, while a more complex arrangement in which the E-
strands form a so-called Leu-Ser (LS) motif that then stack in a parallel in-resister arrangement on 
the fibril long axis were observed in a structure of a fibril formed by AE42 (Figure 5b - left) 27,65. Other 
fibril structures with complex organisation of the E-strands within each rung of the cross-E ladder 
have been observed, including those of D-synuclein55,208 (Figure 5e) and tau28 (Figure 5d). What is 
clear is that very different organisations of polypeptide chains can stack into a fibril that conforms to 
the cross-E structure of amyloid. As more atomic structures of amyloid fibrils are solved, it will be 
interesting to see just how many different organisations of E-strands will fall under the umbrella of 
the cross-E fold. 
 
In all of the amyloid fibril structures determined to date with atomic precision, the E-strands are 
stabilisĞĚďǇĚƌǇ ‘ƐƚĞƌŝĐǌŝƉƉĞƌƐ ?51: tight interfaces of interdigitated hydrophobic side chains that 
exclude water (Figures 4 and 5), and almost perfect packing of their amino acid side chains. These 
zippers appear to be unique to amyloid fibrils, as they have not yet been observed in a globular 
protein or in other natural fibrous proteins51. ŝƐĞŶďĞƌŐ ?Ɛ original description of the steric zipper 
interface was based on structures from microcrystals of short peptides derived from amyloid-
forming proteins, including fragments of AE, tau, PrP, insulin, IAPP, lysozyme, E2m and D-synuclein51. 
This work described eight classes of zipper, four formed from parallel E-strands and four from 
antiparallel E-strands51. Five of the eight proposed structures were observed experimentally51. 
Microcrystals have similarities with fibrils, in that they can grow under similar conditions, have an 
~4.7 Å repeat in their unit cells209 and, in some cases, small changes in conditions drive 
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interconversion of fibrils into crystals and vice versa210. Peptide microcrystals can also seed fibrils of 
similar morphology from the full length protein54, suggesting that steric zippers may be ƚŚĞ ‘ĐŽƌĞ ?ŽĨ
amyloid fibrils formed by their intact protein counterparts54,55. However, the steric zippers identified 
in fragments of tau53 did not form similar zippers in the cryo-EM structure of fibrils formed from the 
full length protein28, although this does not preclude formation of zippers by these regions in tau 
fibrils with different morphologies.  
 
Proteins with a cross-E structure are also found in E-helices211,212. These structures are stabilised by a 
specific pattern of hydrophilic side chains on the outside of the E-helix and hydrophobic side chains 
on the inside, along with a terminal glycine213 (Figure 4b). E-helices have been formed from designed 
peptides214, are found in soluble proteins, including a variety of bacterial lyases215, antifreeze 
proteins216, and viral tail spikes217, and have been implicated in the formation and prionic nature of 
fibrils in fungi and other organisms28,190,218. High resolution structures of tau fibrils determined using 
cryo-EM28 and HET-S from ssNMR66,219 show E-helix motifs with very similar backbones (RMSD 1.3 Å) 
despite low sequence similarity in their E-helical regions. Together, the results highlight the array of 
possible structures that conform to the general amyloid fold, but which differ in the details of how 
their E-strands are arranged.  
 
[H2] Filament Architecture of the Amyloid Fibril  
The morphology of an amyloid fibril is determined by the number and arrangement of 
protofilaments that form the fully assembled fibrils28,64,70-72,203,220, as well as the structure of the 
subunit itself. Variation in the arrangement and type of interactions between protofilaments adds to 
the diversity of the amyloid fold. Some amyloid fibrils are comprised of a single protofilament (e.g. 
the E-helix of Het-S66 (Figures 4b and 5a), but the majority contain multiple 
protofilaments27,28,64,191,220 which twist together68,221-223. Different twists are observed between fibrils 
formed in the same growth mixture70,203,222, and even within a single fibril. Other arrangements of 
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protofilaments have been found, including cylinders224, flat ribbons64,220,223, and pseudo-crystalline 
sheets210. Protofilaments in twisted fibrils have been found with a variety of symmetries viewed 
down the fibril axis as well as paring in an asymmetric manner28. This includes 2 or 3 monomeric 
units in the same plane (in-register 2 and 3-fold) 204,205 and 21 screw symmetries27,28 (a rotation of 
180o followed by a transition of ½ the E-sheet spacing down the fibril axis). In the recent high-
resolution cryo-EM structures of tau and AE42, the protofilaments pack in a parallel manner, giving 
the fibril polarity27,28. In contrast, lower resolution cryo-EM reconstructions of E2m fibrils suggest 
that fibrils constructed from both nonpolar (anti-parallel) and polar (parallel) organisations of 
protofilaments are formed within the same preparation203. However, it should be noted that no 
high-resolution structure of a nonpolar fibril with an antiparallel arrangement of its protofilaments 
has yet been determined. Mass per unit length (MPL) measurements using scanning transmission 
EM (STEM)65,203,220 have been used to determine the number of protofilaments in E2m203, IAPP221, 
and D-synuclein208 fibrils, and to differentiate polymorphs of AE40 with two-fold and three-fold 
symmetric structures (Figure 5c)58,204,205,225. MPL can also be determined by tilt-beam transmission 
EM (TB-TEM) imaging226, or by mass spectrometry of whole fibrils227, although STEM remains the 
most commonly used approach.  
 
The arrangements of the protofilaments in recently determined amyloid fibril structures are shown 
in Figure 5. These include the 2A and 3Q fibrils of AE40 described above (Figure 5c), in which different 
fibril morphologies correspond to different organisation of similar (but not identical) E-loop-E 
subunit motifs204. /ŶŽƚŚĞƌĐĂƐĞƐ ?ŝŶĐůƵĚŝŶŐƚŚĞ ‘ƉĂŝƌĞĚŚĞůŝĐĂů ?ĂŶĚ ‘ƐƚƌĂŝŐŚƚ ?ĨŝůĂŵĞŶƚƐŽĨƚĂƵ28, 
different fibril morphologies are formed by identical subunits held together by different interactions 
(Figure 5d). Although the cryo-EM structures of the tau polymorphs provide the first direct evidence 
for different fibril morphologies arising from alternative packing of identical subunits, this 
phenomenon has been suggested for D-synuclein64,223, AE4071,72, TTR67, and E2m203 fibrils. 
Protofilaments in paired helical filaments of tau28 are stabilised by backbone hydrogen bonding 
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within in its 332PGGGQ336 sequence that forms an anti-parallel poly-glycine II E-spiral228, as well as by 
hydrogen bonding between the sidechain of Gln336 and the backbone of Pro332 in the opposing 
protofilament. In the recent cryo-EM structure of AE4227 the protofilaments were shown to be held 
together by a hydrophobic steric zipper involving the Val39 and Ile41 side chains from each 
protofilament, and stabilised further by a salt bridge between the N-terminal Asp and Lys28 
sidechains of opposing protofilaments (Figure 4c). By contrast, iŶƚŚĞĂƐǇŵŵĞƚƌŝĐ ‘ƐƚƌĂŝŐŚƚĨŝůĂŵĞŶƚ ?
(SF) tau polymorph28, neither backbone nor side chain interactions between protofilaments appear 
to play a large role in stabilising its structure. Rather, six sidechains (K317, K321, and T319 from each 
protofilament) coordinate an unknown density which the authors predict is the N-terminal 7EFE9 of 
each tau subunit. This density could, however, involve another polyanionic molecule such as a 
glycosaminoglycan or nucleic acid in this crude brain extract28. Analyses of amyloid fibrils of D-
synuclein with stripes of high electron density running down the fibril axis223,229 suggest a possible 
role for metal ions in stabilising fibrils, consistent with many studies that have proposed metal ion 
binding in the initiation of amyloid formation230.  
 
Data from X-ray diffraction and micro-ED52 of small, amyloidogenic peptides have been used to 
predict the formation of steric zippers53-55,76. As the crystal packing interactions in these steric 
zippers are necessarily formed between identical peptides, they can only predict regions that self-
associate in symmetric, paired protofilaments. A structure of the non-amyloid component (NAC) 
core domain of D-synuclein by microED55 was interpreted as showing possible candidates for inter-
protofilament steric zippers in fibrils formed from the intact 140-residue protein. Despite 
identification of several polymorphs of D-synuclein fibrils composed of twisted protofilaments220,223, 
as yet no high-resolution structure of D-synuclein fibrils containing multiple protofilaments is 
available to validate this hypothesis.  
 
The recent structures of amyloid fibrils show that the same primary sequence can assemble into 
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different structures, even under the same growth conditions76,231-233. This is in stark contrast with the 
folding of the vast majority of globular proteins, where a given sequence forms the same fold every 
time it emerges from the ribosome or is folded in vitro234. Moreover, amyloid formation is slow, 
despite being thermodynamically favoured, so it can take an extraordinarily long time, possibly years 
in vitro235, for fibril growth to reach equilibrium. Thus, the morphology of fibrils can change over 
time235 and in response to changing environmental conditions77. In energetic terms, the energy 
landscape of fibril formation is far more rugged and complex than that for globular proteins, 
potentially involving multiple intermediates, parallel assembly pathways and resulting in diverse 
amyloid end products with different cross-E structures236.  
 
[H1] Amyloid Polymorphism in Disease 
How the observed structural polymorphism of amyloid fibrils affects disease onset, progression and 
presentation is not well understood. What is clear is that variations in ƚŚĞƉƌĞĐƵƌƐŽƌƉƌŽƚĞŝŶ ?ƐŐĞŶĞ
sequence can be directly tied to variation in both the age of onset and disease duration in numerous 
amyloid diseases (Figure 6). While the development of disease can take place over different 
timescales in individuals affected by polyQ expansion diseases (Figure 6, top left), AD (Figure 6, top 
right) and PD (Figure 6, bottom left), in prion diseases death is observed over an extraordinarily 
narrow window of a few days237. Humans also show extended incubation periods in CJD238, but have 
short disease duration (typically six months), unique (so far) to these diseases. By contrast with prion 
disorders, mouse models of AD result in death over a much wider time span239, as is observed in 
humans60, although the ability for mouse models to accurately recapitulate disease processes in 
humans is debated239. In ,ƵŶƚŝŶŐƚŽŶ ?ƐĚisease, individuals containing huntingtin with less than 35 
glutamine (Q) residues appear healthy over their lifetime. However, individuals with longer polyQ 
repeat lengths show an age of onset and severity of disease which correlates with the number of Q 
residues above this critical threshold104 (Figure 6, top left). In Machado-Joseph disease, another 
polyQ disorder in which ataxin 3 contains a glutamine expansion, the non-pathological polyQ repeat 
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length is 12-40 residues, with pathology not presenting until 62 repeats104. The wide range in 
number of repeats, coupled with the fact that increasing the number of repeats increases the 
severity of disease symptoms, suggests that polymorphic effects due to primary sequence expansion 
can be linked with disease104.  
 
PD can be caused by mutations within the SNCA gene that encodes D-synuclein, with variants such 
as A30P, E46K, H50Q, G51D and A53T leading to early onset disease and shorter disease duration 
(Figure 6, lower left)101,240-243. For example, the G51D variant is as aggressive as quadruplication of 
the SNCA gene in terms of age of disease onset, but has also been shown to induce pyramidal signs 
and epilepsy244. Whilst gene multiplication decreases the age of onset of PD, as expected from an 
increased concentration of the precursor protein, the additional symptoms in patients with SNCA 
gene multiplications cannot be accounted for simply by amyloid load. This adds weight to the view 
that specific amyloid polymorphs may explain the observed phenotypes of PD244. Specific point 
mutations can give rise to diverse effects on cognitive impairment, psychiatric disturbances, 
hallucinations, autonomic dysfunction, as well as the previously mentioned symptoms244.  
 
Primary sequence variations including sequence expansions (such as polyQ, polyA and poly-GlyAla 
expansions92) or single point mutations (such as those described for D-synuclein above) may affect 
subunit packing in the fibril itself. Consistent with this notion, ssNMR studies of fibrils formed from 
ƚŚĞ ‘KƐĂŬĂ ? A?22) ĂŶĚ ‘/ŽǁĂ ? ?23N) mutants of AE40 revealed structures that are different to those 
formed by wild-type AE40/4261,245. Links between polymorphism and pathology in fibrils with identical 
primary sequences are less clear, but still evident. Different polymorphs of AE40246 and D-synuclein220 
have different cytotoxicity in vitro, and different rates of plaque deposition in vivo based on the 
source of the fibrillar seed material247,248. Different cytotoxicity was also observed in fibrils of full 
length IAPP seeded from toxic and non-toxic short peptide fibrils54. Isolation and characterisation of 
fibrils from patients also suggests that fibril morphology varies from patient to patient. As discussed 
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above, seeding fibril formation of AE40/42 using plaques extracted from patients who displayed 
different disease phenotype and progression resulted in different ssNMR spectra ,60,205, suggesting 
that a different fibril polymorph was predominant in each patient. This is not to suggest that all 
fibrils formed in vivo will be monomorphic. Indeed, multiple polymorphs of tau were present in a 
single patient-derived sample28 ĂŶĚǀĂƌŝŽƵƐɴpolymorphs have been identified within the same 
patients using X-ray diffraction249. Further evidence comes from analysis of fibrils seeded from ex 
vivo material from patients who presented either the posterior cortical atrophy form of AD (PCA-
AD), rapid-AD (r-AD) or typical AD (t-AD)60. A single Aɴ40 polymorph was most abundant in PCA-AD 
and t-AD, whereas the r-AD samples contained a higher proportion of additional structures. Again, 
the ex vivo samples were structurally distinct from synthetic strains created in vitro, highlighting 
remarkable strain polymorphism even within an individual patient60. 
 
The diversity of amyloid polymorphs could explain the different disease phenotypes observed in 
patients in which the same amyloid precursor protein aggregates. Alternatively, given that fibril 
formation can take years to reach equilibrium235, fibrils may slowly change in structure. Indeed, fibril 
ƉůĂƋƵĞƐŽĨɴŝŶƚƌĂŶƐŐĞŶŝĐŵŽƵƐĞŵŽĚĞůƐhave been shown to undergo structural rearrangement250 
and different D-synuclein fibril polymorphs evolve over time in vitro235. Fibril structures in patients 
may thus vary during disease progression. Such findings may explain why amyloid plaque load does 
not correlate with disease symptoms251,252 and thus confirmation of fibril structure post mortem is 
needed to link fibril structure with disease type. Such studies are in their infancy, but with 
development of better diagnostics may help to identify patients in most need of urgent therapeutic 
intervention. Disease is currently diagnosed using cerebral spinal fluid diagnostics, positron electron 
transmission (PET) imaging, and detection of oligomers using immunoassays, including 
conformation-dependent approaches253. However, personalised amyloid-blocking medicines tailored 
to the specific amyloid polymorphs present in individual patients remain an aspiration. At present, 
with one notable exception254, no therapeutics have been shown to reduce amyloid formation in 
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humans. 
 
Another important consideration in targeting these devastating diseases is where in the amyloid 
aggregation cascade or disease process to intervene. This is exacerbated by the dynamic nature of 
the precursors of amyloid formation that are unfolded, non-native, or partially folded, precluding 
structure based drug design. Decreasing the concentration of monomer would reduce the total 
amount of protein available to form amyloid, but such strategies could be deleterious if the 
monomer has a vital functional role. Interestingly, however, the function of several amyloid proteins 
remains unresolved255,256. Equally problematic, reducing the concentration of a functional monomer 
may have other deleterious effects. Perturbing oligomer formation (Figure 2) may offer a route to 
treatment, but the dynamic nature of these species makes them difficult to target257 and no high 
resolution amyloid oligomer structures are currently available to guide such efforts. Decreasing the 
population of any one oligomer may drive the equilibrium toward a more toxic assembly. Small 
molecules could be sought to prevent oligomer formation or, conversely, to promote fibrillation 
which, in turn, would decrease the lifetime and hence toxic potential of the oligomeric species. 
Designing interventions that promote the assembly of less toxic fibril polymorphs might also reduce 
disease severity. Another approach would be to promote the sequestration of amyloidogenic 
monomers into non-amyloid amorphous aggregates258, although this could itself have deleterious 
effects.  Finally, preventing the spread of toxic species may offer a new form of intervention. 
Oligomers have been shown to interact with many cellular surface receptors in both pre- and post-
synaptic membranes such as EphB2, PrPC 259, RAGE, SCARA/B mediating both their toxic effects and 
internalisation. Other cell surface receptors such as LAG3260 have been shown to be important for 
endocytic import of fibrillar species. Containing toxic species in individual affected cells and/or 
preventing uptake by antibody blocking of receptors260 may prevent the prion-like spread and hence 
may halt the progression of disease. Knowing where to intervene relies on identifying the toxic 
species in amyloid aggregation, which may depend on the protein sequence and/or the cell types 
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involved. Culprits could include any or all of on-pathway and off-pathway oligomers as well as the 
fibrils themselves261.  
  
Whilst effective therapy still currently remains out of reach, both drug-dependent and resistant 
strains of prion diseases have been reported262-264 suggesting an opportunity for therapeutic 
intervention does exist. Moreover, small molecules, peptides, and peptidomimetics able to target 
different, but closely related, steric zippers have been successfully designed265-267, giving hope that 
we will soon be able to identify which amyloid fibrils form in different individuals, and hence to 
relate amyloid structure and assembly to disease type and aetiology.  
 
Conclusion 
Amyloid fibrils have highly organised hierarchical structures that are built from protofilaments in 
which individual monomeric subunits form (most often) parallel in register E-strands. These 
protofilaments then pack against each other, forming fibrils that are stabilised by dry steric 
interfaces. Further inter-fibril interaction leads to the formation of the plaques and inclusions 
characteristic of amyloid disease. Recent advances in cryo-EM and ssNMR have given  insights into 
the structure of amyloid fibrils in unprecedented detail, revealing a variety of structures that 
conform to the cross-E amyloid fold. Coupling these techniques with orthogonal data, for example 
with other biophysical measurements, and data on disease type, presentation and progression, will 
help to elucidate which amyloid formation pathway(s), amyloid intermediates and/or fibril 
structures are responsible for disease. As the capabilities of  cryo-ET improve, we will be able to 
study amyloid fibrils and plaques and intracellular inclusions in situ with increased resolution. This 
will allow us to discern how polymorphism relates to disease phenotype and how fibril structure 
affects, and is affected by, the cellular environment. The time has never been better to finally 
understand amyloid structure, protein aggregation mechanisms and how they relate to disease. In 
turn, these breakthroughs bring new hope and renewed vigour in our quest to develop agents that 
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can diagnose, delay or even halt the progression of disease. 
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Figures and Figure Legends  
Box 1: The progression of electron microscopic observation of amyloid fibril structures over the 
last 20 years. Although the use of electron microscopy to examine amyloid fibril structure has a long 
history201,268,269, determination of atomic resolution structures only became a possibility with the 
advent of cryo-EM. This led to several fibril structures at intermediate resolutions68,71,72,202,203,222. 
While, this gave information about gross fibril morphology, it could not be used to build atomic 
models. Only in the past year have cryo-EM structures reached the resolution where atomic detail 
cam be resolved27,28. This has been driven by technological advances in microscope and electron 
detection equipment and improvements in image processing software80. The increase in achievable 
resolution of cryo-EM reconstructions of fibrils is illustrated with structures of fibrils formed from a) 
SH3 domains68, b) prion protein, PrP202, c) AE40 formed in vitro71 and d) ex vivo tau28. Upper scale 
bars are 5 nm, lower are 50 nm.  
 
Figure 1: Progression of amyloid structure research over close to 400 years that has culminated in 
the first atomic structures of amyloid fibrils. The timeline displays the history of key discoveries in 
the amyloid field from the initial identification of amyloid, to discoveries that led to the first 
structures of amyloid fibrils associated with disease in all-atom detail. References to the key 
discoveries are shown within the figure and can be found in the reference list.  
 
Figure 2: Schematic of amyloid formation. Native proteins are in dynamic equilibrium with their less 
structured, partially folded and/or unfolded states. One (or possibly several) of these states initiate 
amyloid fibril formation by assembling into oligomeric species. The precursor of aggregation (native, 
partially folded or unfolded) may differ for different protein sequences. Oligomeric species can then 
assemble further to form higher order oligomers, one or more of which can form a fibril  nucleus 
which, by rapidly recruiting other monomers, can nucleate assembly into amyloid fibrils. As fibrils 
grow, they can fragment, yielding more fibril ends that are capable of elongation by the addition of 
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new aggregation-prone species134,138,139. This results in an exponential growth of fibrillar material 
(blue line) until nearly all free monomer is converted into a fibrillar form. Fibrils are dynamic and can 
release oligomers that may or may not be toxic170. Fibrils can also associate further with each other, 
with other proteins and with non-proteinaceous factors180 (not shown here) to form the amyloid 
plaques and intracellular inclusions characteristic of amyloid disease. 
 
Figure 3: Amyloid aggregates can cause cell disruption by a variety of mechanisms. Amyloid 
aggregates can deposit extracellularly or intracellularly, and both can give rise to cellular dysfunction 
and disease. The aggregates that form from different protein precursors may have different cellular 
effects, but deconvoluting the toxic mechanism of an individual protein and its ensemble of 
misfolded or aggregated states (misfolded monomers, oligomers, fibrils or plaques and intracellular 
inclusions) remains a challenge. Plaques and inclusions sequester a range of other molecules that 
includes glycosaminoglycans12,180, lipids152,270 and metal ions230, which stabilise their assembly. 
Plaques are physically large and can disrupt organ function by their sheer size. Small fibrils can also 
be taken up into a cell via endocytosis, but this can be perturbed by preventing binding to certain 
cell surface receptors such as lymphocyte-activation gene 3260. Within endosomes and lysosomes 
fibrils can release toxic oligomers and also can disrupt endosomal and lysosomal function and 
dynamics since fibrils are highly resilient to degradation 182,271. Fibrils can also access the intracellular 
space following release from cells, thus spreading of disease by uptake into adjacent cells. Other 
effects of aggregates within cells include disruption of endoplasmic reticulum (ER) dynamics 84, 
release of reactive oxygen species (ROS)150 from mitochondria, and the induction of stress 
responses117 (not shown here).  
 
Figure 4: Structural motifs that stabilise amyloid fibrils. (a) A 10 residue peptide from TTR, showing 
E-sheet stacking in which each E-ƐƚƌĂŶĚ ‘ƌƵŶŐ ?ŝƐƐƚĂďŝůŝƐĞĚďǇŚǇĚƌŽŐĞŶďŽŶĚƐďĞƚǁĞĞŶƚŚĞ
polypeptide backbones of precursors, which are separated by the canonical 4.7/4.8 Å repeat of the 
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cross-E amyloid fold (pdb 2nm567). Further stabilisation is provided by a steric zipper between the E-
sheets which stabilises the fibril core. (b) The E-helix of HET-S illustrating its steric zippers (pdb 
2rnm66). (c) A structure of AE42 fibrils (pdb 5oqv27) illustrating the variety of interactions that stabilise 
the fibril, including E-strand stacking (top left); formation of inter-protofilament salt bridges (top 
right); intra-protofilament steric zippers (bottom left) and inter-protofilament steric zippers (bottom 
right).  
 
Figure 5: Subunit packing in amyloid fibrils. Space filling representations of near-atomic resolution 
models of different amyloid fibrils, each filtered to 4 Å. Individual subunits are coloured in red to 
highlight different inter-protofilament packing in different fibril types. A) The E-helix of HET-S that 
forms a single filament (pdb 2lbu66). b) Two polymorphs of AE42 fibrils formed under different 
growth conditions (pdb 5oqv27) (left) and pdb 5kk3272 (right). c) Two polymorphs of AE40. Fibrils 
formed under the same solution conditions, but propagated from seeds with different morphologies 
(2A, pdb 2lmn204) (left) and (3Q, pdb 2lmp204) (right). d) Two polymorphs of tau fibrils, paired helical 
(PHF) (left) (pdb 5o3l28 and straight (SF) (right) (pdb 5oet28). e) The single filament of D-synuclein 
fibrils (pdb 2n0a208). The main chain of the top layer of polypeptide chain in each fibril is shown in 
red. 
 
Figure 6: How changes in primary sequence affect amyloid disease. (Top left) Different diseases 
(listed) are caused by polyglutamine (polyQ) expansion disorders. Depending on the specific disease 
(shown in the figure) polyQ repeat lengths exceeding a critical threshold can cause disease, whereas 
fewer repeats are innocuous. Data were taken from92,104. (Lower left) The age of onset of patients 
with PD is influenced by the copy number of the ɲ-synuclein gene (duplication (2SNCA), triplication 
(3SNCA) or quadruplication (4SNCA)), with increased expression correlating with earlier onset. Age 
of onset and disease duration are also influenced by single point mutations, which may result in 
different aggregation pathways and/or kinetics, or different fibril architectures resulting in different 
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disease phenotypes. Data were taken from273,274. (Top right) The pathology of AD can be influenced 
by fibril morphology. In particular typical-AD and a rapidly progressive form of AD (Rapid-AD) show 
similar fibril architecture monitored by ssNMR, but have varied ages of onset and disease duration. 
,ŽǁĞǀĞƌŝŶƉŽƐƚĞƌŝŽƌĐŽƌƚŝĐĂůĂƚƌŽƉŚǇůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?W-AD), fibrils with a different structure 
are formed. The age of onset and disease duration for PCA-AD are similar to typical-AD and rapid-
AD, but the disease primarily affects the cerebellum rather than the temporal lobe. Adapted from 60. 
(Centre) A diagram of the brain highlighting the regions primarily affected by each of the diseases 
shown.  
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Tables  
 
Table 1: Protein precursors associated with amyloid disease.  
Footnote: Each protein precursor is listed, alongside the size and structure of the precursor and the 
disease with which it is associated. Data were taken from references6,87.  
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Glossary of Terms 
 
Amyloid: Fibrils formed from proteins, marked by a characteristic cross-E organisation with a ~4.7-
4.8 Å repeat running down the fibril axis.  
Amyloidoses: A class of diseases associated with the formation of amyloid fibrils, tangles and 
plaques, although the causative agents of disease have yet to be determined definitively. 
Biofilm: A group of microorganisms that have adhered to each other and/or a surface. 
Cross-E: The structural motif consisting of E-strands organised perpendicular to the axis of a fibril 
and stabilised by inter-strand hydrogen bonds and dry steric zipper interfaces between adjacent E-
sheets. 
Crossover: dŚĞĚŝƐƚĂŶĐĞŝƚƚĂŬĞƐĂĨŝďƌŝůƚŽĂĐŚŝĞǀĞ ? ? ?ȗĚĞŐƌĞĞƐŽĨƌŽƚĂƚŝŽŶ ? This appears as the 
distance between the two narrowest points on a 2D EM or AFM image of a twisted fibril. 
Gram Positive Bacteria: Bacteria that possess a cell wall made of peptidoglycan which can be 
positively stained with crystal violet dye, known as Gram stain.  
Fibril Load: A measure of the total amount of amyloid fibril within a sample or patient. 
Haemodialysis: A dialysis-based filtration treatment than acts to replace kidney function in patients 
experiencing kidney failure.  
Long-term Potentiation: A persistent increase in synaptic strength after stimulation of the synapse 
Native Protein: The properly assembled form of a protein required for functionality.  
Polymorphism: The same protein can assemble into amyloid fibrils that have different arrangements 
of subunits in the fibril, numbers of protofilaments, widths, and/or crossover distances. 
Pi Stacking Interaction: An attractive non-covalent interaction involving the S electrons in aromatic 
rings.  
Prion: A class of infectious amyloid fibrils 
Protofilament: A structural component of an amyloid fibril with a cross-E structure that twists 
together with one or more additional protofibrils to form a mature amyloid fibril.  
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Protofibril: An intermediate formed transiently during amyloid fibril assembly. Protofibrils do not 
necessarily contain a cross-E structure characteristic of protofilaments and mature amyloid fibrils. 
Subunit: The smallest unit that makes up an amyloid fibril. Generally a single copy of the precursor 
protein. 
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DISEASE 
AGGREGATING PROTEIN OR 
PEPTIDE 
NUMBER OF 
AMINO ACIDS 
NATIVE STRUCTURE OF PROTEIN OR PEPTIDE 
NEURODEGENERATIVE DISEASES 
>,/DZ ?^/^^ ŵǇůŽŝĚɴƉĞƉƚŝĚĞ 40 or 42 Natively unfolded 
FAMILIAL ENCEPHALOPATHY WITH NEUROSERPIN 
INCLUSION BODIES 
Neuroserpin 410 ɲA?ɴ 
VARIOUS NEURODEGENERATIVE DISORDERS Actin ~400 DŽƐƚůǇɲ ?ƐŽŵĞɴ 
NEUROFERRITINOPATHY Ferritin 175 or 183 ůůɲ 
SPONGIFORM ENCEPHALOPATHIES Prion protein or fragments thereof 253 
Natively unfolded (residues 1̽ ? ? ? )ĂŶĚɲ-helical 
(residues 121̽230) 
WZ</E^KE ?^/^^ ɲ-Synuclein 140 Natively unfolded 
DEMENTIA WITH LEWY BODIES ɲ-Synuclein 140 Natively unfolded 
FRONTOTEMPORAL DEMENTIA WITH PARKINSONISM Tau 352̽441 Natively unfolded 
AMYOTROPHIC LATERAL SCLEROSIS Superoxide dismutase 153 All-ɴ ?/ŐůŝŬĞ 
,hEd/E'dKE ?^/^^D Huntingtin with polyQ expansion 3144 Largely natively unfolded 
SPINOCEREBELLAR ATAXIAS Ataxins with polyQ expansion 816 
All-ɴ ?y,ĚŽŵĂŝŶ ?ƌĞƐŝĚƵĞƐ ? ? ?̽694); the rest are 
unknown 
SPINOCEREBELLAR ATAXIA 17 
TATA box-binding protein with 
polyQ expansion 
339 
ɲA?ɴ ?dWůŝŬĞ ?ƌĞƐŝĚƵĞƐ ? ? ?̽339); unknown (residues 1̽
158) 
SPINAL AND BULBAR MUSCULAR ATROPHY 
Androgen receptor with polyQ 
expansion 
919 
All-ɲ ?ŶƵĐůĞĂƌƌĞĐĞƉƚŽƌůŝŐĂŶĚ-binding domain (residues 
669̽919); the rest are unknown 
HEREDITARY DENTATORUBRAL-PALLIDOLUYSIAN 
ATROPHY 
Atrophin-1 with polyQ expansion 1185 Unknown 
FAMILIAL BRITISH DEMENTIA ABri 23 Natively unfolded 
FAMILIAL DANISH DEMENTIA ADan 23 Natively unfolded 
NON-NEUROPATHIC SYSTEMIC AMYLOIDOSES 
52 
 
AL AMYLOIDOSIS 
Immunoglobulin light chains or 
fragments 
~90 All-ɴ ?/ŐůŝŬĞ 
AH AMYLOIDOSIS 
Immunoglobulin heavy chains or 
fragments 
~220 All-ɴ ?/ŐůŝŬĞ 
AA AMYLOIDOSIS 
Fragments of serum amyloid A 
protein 
76̽104 All-ɲ ?ƵŶŬŶŽǁŶĨŽůĚ 
FAMILIAL MEDITERRANEAN FEVER 
Fragments of serum amyloid A 
protein 
76̽104 All-ɲ ?ƵŶŬŶŽǁŶĨŽůĚ 
SENILE SYSTEMIC AMYLOIDOSIS Wild-type transthyretin 127 All-ɴ ?ƉƌĞĂůďƵŵŝŶůŝŬĞ 
FAMILIAL AMYLOIDOTIC POLYNEUROPATHY Mutants of transthyretin 127 All-ɴ ?ƉƌĞĂůďƵŵŝŶůŝŬĞ 
HAEMODIALYSIS-RELATED AMYLOIDOSIS ɴ ?-microglobulin 99 All-ɴ ?/ŐůŝŬĞ 
APOAI AMYLOIDOSIS 
N-terminal fragments of 
apolipoprotein AI 
80̽93 Natively unfolded 
APOAII AMYLOIDOSIS 
N-terminal fragment of 
apolipoprotein AII 
98 Unknown 
APOAIV AMYLOIDOSIS 
N-terminal fragment of 
apolipoprotein AIV 
׽70 Unknown 
APOCII AMYLOIDOSIS ApoCII 79 ɲA㴀 unstructured 
APOCIII AMYLOIDOSIS ApoCIII 79 ɲA㴀 ƵŶƐƚƌƵĐƚƵƌĞĚ 
FINNISH HEREDITARY AMYLOIDOSIS Fragments of gelsolin mutants 71 Natively unfolded 
LYSOZYME AMYLOIDOSIS Mutants of lysozyme 130 ɲA?ɴ ?ůǇƐŽǌǇŵĞĨŽůĚ 
FIBRINOGEN AMYLOIDOSIS Variants of fibrinogen ɲ-chain 27̽81 Unknown 
ICELANDIC HEREDITARY CEREBRAL AMYLOID 
ANGIOPATHY 
Mutant of cystatin C 120 ɲA?ɴ ?ĐǇƐƚĂƚŝŶůŝŬĞ 
NON-NEUROPATHIC LOCALISED DISEASES 
TYPE II DIABETES 
Amylin, also called islet amyloid 
polypeptide (IAPP) 
37 Natively unfolded 
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AORTIC MEDIA AMYLOIDOSIS Lactadherin C2-like domain 50 Unfolded 
LECT2 AMYLOIDOSIS Leukocyte chemotactic factor-2 151 Unknown 
LOCALISED CUTANEOUS AMYLOIDOSIS Gelactin-7 136 All-ɴ 
HYPOTRICHOSIS SIMPLEX OF THE SCALP Corneodesmosin 
529 
(truncations 
cause 
amyloid) 
Unknown 
CALCIFYING EPITHELIAL ODONTOGENIC TUMOURS 
Odontogenic ameoblast-associated 
protein 
153 Unknown 
SENILE SEMINAL VESICLE AMYLOIDOSIS Semenogelin 1 462 Unknown 
MEDULLARY CARCINOMA OF THE THYROID Calcitonin 32 Natively unfolded 
ATRIAL AMYLOIDOSIS Atrial natriuretic factor 28 Natively unfolded 
HEREDITARY CEREBRAL HAEMORRHAGE WITH 
AMYLOIDOSIS 
DƵƚĂŶƚƐŽĨĂŵǇůŽŝĚɴƉĞƉƚŝĚĞ 40 or 42 Natively unfolded 
PITUITARY PROLACTINOM Prolactin 199 All-ɲ ? ?-helical cytokines 
INJECTION-LOCALIZED AMYLOIDOSIS Insulin 21 + 30 All-ɲ ?ŝŶƐƵůŝŶůŝŬĞ 
INJECTION-LOCALIZED AMYLOIDOSIS Enfuvirtide 36 Unstructured 
AORTIC MEDIAL AMYLOIDOSIS Medin 50 Unknown 
HEREDITARY LATTICE CORNEAL DYSTROPHY 
Mainly C-terminal fragments of 
kerato-epithelin 
50̽200 Unknown 
CORNEAL AMYLOIDOSIS ASSOCIATED WITH TRICHIASIS Lactoferrin 692 ɲA?ɴ ?ƉĞƌŝƉůĂƐŵŝĐ-binding protein like II 
CATARACT ɶ-Crystallins Variable All-ɴ ?ɶ-crystallin like 
CALCIFYING EPITHELIAL ODONTOGENIC TUMOURS Unknown ׽46 Unknown 
PULMONARY ALVEOLAR PROTEINOSIS Lung surfactant protein C 35 Unknown 
INCLUSION-BODY MYOSITIS ŵǇůŽŝĚɴƉĞƉƚŝĚĞ 40 or 42 Natively unfolded 
CUTANEOUS LICHEN AMYLOIDOSIS Keratins Variable Unknown 
 
